In-hospital outcomes after emergency or prophylactic veno-arterial extracorporeal membrane oxygenation during transcatheter aortic valve implantation: a comprehensive review of the literature.


Journal

Perfusion
ISSN: 1477-111X
Titre abrégé: Perfusion
Pays: England
ID NLM: 8700166

Informations de publication

Date de publication:
07 2019
Historique:
pubmed: 12 1 2019
medline: 4 3 2020
entrez: 12 1 2019
Statut: ppublish

Résumé

Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) has been used to deal with life-threatening complications as well as back-up or active cardiovascular support during high-risk procedures in patients undergoing transcatheter aortic valve implantation (TAVI). PubMed and MEDLINE electronic databases were searched in order to identify studies with emergency or prophylactic V-A ECMO application in association with TAVI procedures. From November 2012 to November 2017, 14 relevant studies were identified that included 5,115 TAVI patients of whom 102 (2%) required V-A ECMO (22 prophylactically, 66 as an emergency and 14 without a reported indication). The reason for emergency V-A ECMO institution was detailed in 64 patients: left ventricle free wall rupture (n = 14), haemodynamic instability (n = 12), ventricular arrhythmias (n = 7), aortic annulus rupture (n = 6), coronary obstruction (n = 6), low left ventricular output (ejection fraction <35%) (n = 5), uncontrollable bleeding (n = 5), severe aortic regurgitation (n = 4), prosthesis embolisation (n = 3), aortic dissection (n = 1) and respiratory failure (n = 1). Femoral arterial and vein cannulation was the most common access technique for V-A ECMO institution. Major bleeding (n = 7) and vascular access complications (n = 7) were reported after ECMO institution. The overall in-hospital survival was 73% (61% in the emergency vs. 100% in the prophylactic group). V-A ECMO support should be available at any centre performing TAVI and provides effective mechanical circulatory support in an emergency setting. We present an algorithm to aid decisions about prophylactic circulatory assistance with V-A ECMO and it should form part of the heart team discussion before a TAVI procedure is undertaken.

Identifiants

pubmed: 30632894
doi: 10.1177/0267659118816555
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

354-363

Investigateurs

Marco Turrisi (M)
Caterina Gandolfo (C)
Giuseppe Montalbano (G)
Stefano Cannata (S)
Valeria Lo Coco (VL)
Alessandro Armaro (A)
Vincenzo Stringi (V)
Giuseppe Romano (G)
Calogero Falletta (C)
Thijs Delnoij (T)
Martijn Gilbers (M)
Sam Heuts (S)
Rick Schreurs (R)
Federica Jiritano (F)
Matteo Matteucci (M)
Dario Fina (D)

Auteurs

Giuseppe M Raffa (GM)

1 Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands.
2 Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation and Department of Anaesthesia and Intensive Care, IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Palermo, Italy.

Mariusz Kowalewski (M)

3 Clinical Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior in Warsaw, Poland.
4 Cardiothoracic Research Centre, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.

Paolo Meani (P)

5 Intensive Care Unit, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands.
6 Cardiology Departments, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands.

Fabrizio Follis (F)

2 Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation and Department of Anaesthesia and Intensive Care, IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Palermo, Italy.

Gennaro Martucci (G)

2 Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation and Department of Anaesthesia and Intensive Care, IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Palermo, Italy.

Antonio Arcadipane (A)

2 Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation and Department of Anaesthesia and Intensive Care, IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Palermo, Italy.

Michele Pilato (M)

2 Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation and Department of Anaesthesia and Intensive Care, IRCCS-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Palermo, Italy.

Jos Maessen (J)

1 Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands.

Roberto Lorusso (R)

1 Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH